@HedgehogTrader Price action in the UK is now at 3.5pence (GBP) so 4.6cent (USD) equivalent…let’s hit that trigger shall we…?! 😉🤘 #coin $CINGF @CoinsiliumGroup#btc
@tom_the_bomb__@Decscfc1990 Also, as an aside, huge thanks for your commentary, updates & musings over the years! Has made the wait more bearable, & has solidified the #avct investment case for me! Here’s hoping for positive outcomes for us all, most importantly those who will benefit from the drugs! 🤞🙂
@tom_the_bomb__@Decscfc1990 Hey Tom! Fair shout! Guess time will tell! Ultimately I’ll be over the moon with any positive update whenever it lands, am invested with what feels comfortable & will add further if things develop well. Ultimately we’re at the mercy of what and when #avct want to release info 🙂
@BenHarper121292@Share_Talk Think you could read across in two ways.
1. As a competitor, not valid imo as their tech is pricey, slow (being patient specific) and only for one form of cancer.
2. The money that piled in, in very dramatic fashion when the data landed.
At least that’s my thoughts! 🤷♂️ #avct
$AVCT holders should note the Samsung Biologics news, even though there’s no direct link.
Samsung’s proposed $1.8B all-cash bid for Swiss CDMO PolyPeptide (closing targeted end-2026) is a bet on one thing: peptide manufacturing demand, driven by GLP-1s.
The read-through most people will miss:
When a CDMO giant pays up 40% over pre-rumor levels to secure peptide synthesis capacity, it tells you the supply chain for peptide chemistry is being built out ahead of demand, not behind it.
Avacta’s pre|CISION platform is peptide-based. Its clinical assets will eventually need commercial-scale peptide manufacturing.
The inference (mine, not the deal’s): capacity consolidation at the manufacturing layer usually precedes a licensing and M&A cycle in the platforms that feed it.
$AVCT
@asininitybeyond Plus they’ve already put exatecan on a cake, so, why not…! 😉😂
Seriously though, think the premise and reasoning is sound, and would be a huge additional string to their bow…guess we’ll find out soon enough 🤞🙂
#AVCT
It’s been highly impressive to watch the speed at which @coughlin582 and her team have expedited AVA6103 and AVA6207 since I joined the board of #AVCT a little over 6 months ago.
The pre|CISION technology which sits behind these drugs is nothing short of groundbreaking.
@Riccardino999@ElkHunter78 If you properly researched you’d see that this isn’t ’curing cancer’ & the issue of mgmt buying was answered in the webinar, amongst other things ‘inside knowledge’ of results precludes them from doing so, oh & the 1 in 11…old news, recent results are far more compelling. #avct